Abstract | PURPOSE: PATIENTS AND METHODS:
Cyclin D1 expression was assessed immunohistochemically and its association with clinico-pathological parameters was analyzed in 1003 breast cancer patients. RESULTS:
Cyclin D1 was over-expressed in 59.4% (596/1003) of cases and significantly associated with a subset of breast cancers having favorable prognostic features, such as low grade (p < 0.0001), low stage (p = 0.0276), estrogen receptor (p < 0.0001) and progesterone receptor positive (p < 0.0001) tumors. An inverse association was found with triple negative breast cancers (p < 0.0001). More importantly, cyclin D1 expression was an independent predictor of favorable overall survival in our cohort (hazard ratio = 0.70; 95% confidence interval = 0.50-0.98; p = 0.0395). Also, tumors that highly expressed cyclin D1 had a longer recurrence-free survival. However, this significant association was seen only in univariate analysis. We also found cyclin D1 to be associated with phospho-Rb in luminal subtype of breast cancer and co-expression of both these markers was an independent predictor of luminal A breast cancer. CONCLUSION:
|
Authors | Abdul K Siraj, Sandeep Kumar Parvathareddy, Padmanaban Annaiyappanaidu, Saeeda O Ahmed, Nabil Siraj, Asma Tulbah, Fouad Al-Dayel, Dahish Ajarim, Khawla S Al-Kuraya |
Journal | OncoTargets and therapy
(Onco Targets Ther)
Vol. 14
Pg. 3309-3318
( 2021)
ISSN: 1178-6930 [Print] New Zealand |
PMID | 34040395
(Publication Type: Journal Article)
|
Copyright | © 2021 Siraj et al. |